menu search

SGEN / Seagen's stock surges 15% after a report that Pfizer is in talks to buy the cancer-focused biotech

Seagen's stock surges 15% after a report that Pfizer is in talks to buy the cancer-focused biotech
Pfizer is in early talks to acquire cancer drugmaker Seagen in a potentially multibillion-dollar deal, The Wall Street Journal reported Monday. Read More
Posted: Feb 27 2023, 08:50
Author Name: Business Insider
Views: 1224100

SGEN News  

Seagen 3Q revenue beat driven by jump in product sales

By Proactive Investors
November 1, 2023

Seagen 3Q revenue beat driven by jump in product sales

Seagen reported mixed third quarter earnings, with revenue outperforming expectations on strong product sales growth as earnings fell short of estimat more_horizontal

Signal Says Buy Calls on This Biotech Stock

By Schaeffers Research
September 25, 2023

Signal Says Buy Calls on This Biotech Stock

Biotech stock Seagen Inc (NASDAQ:SGEN) scored an all-time high of $215.04 today, building on a Friday breakout from a consolidation between $204 and more_horizontal

Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study

By Zacks Investment Research
September 25, 2023

Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metas more_horizontal

Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

By Zacks Investment Research
August 17, 2023

Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla. more_horizontal

Seagen's breast cancer therapy meets main goal in late-stage study

By Reuters
August 16, 2023

Seagen's breast cancer therapy meets main goal in late-stage study

Seagen said on Wednesday its breast cancer therapy in combination with Roche's Kadcyla helped extend the time patients lived without their disease pro more_horizontal

FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?

By The Motley Fool
May 24, 2023

FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?

There isn't much overlap between Amgen's business and Horizons', but that isn't stopping the FTC from looking to block the deal. Pfizer has a strong o more_horizontal

Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?

By MarketBeat
May 19, 2023

Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?

Pfizer Inc. NYSE: PFE continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.'s N more_horizontal

Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows

By CNBC
May 17, 2023

Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows

The debt offering by Pfizer to buy cancer drug maker Seagen comes as Apple, Merck and T-Mobile tap the U.S. bond market ahead of the debt ceiling stan more_horizontal


Search within

Pages Search Results: